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Poster Session II S271independently associated with platelet engraftment.While in pediat-
ric patients only infused CD34+ cells/kg was significantly associated
with platelet engraftment.
Graft-versus-host disease: At days 100, the cumulative incidence
was 55.0% for grade II-IV aGVHD, and 23.1% for grade III-IV
aGVHD. While cGVHD 44.67%, with 21.3% for limited and
23.3% for extensive. In patients under 14 years old, the cumulative
incidence of aGVHDof grade II-IVwas 57.2%, and 13.8% for grade
III-IV.While cGVHD 56.7% for total and 29.5% for extensive. No
associations of HLA disparity with incidence and severity of GVHD
were found.
KIR ligand mismatch and a higher dose of CD56bright NK cells
(41.9 106/kg) in the allografts are associated with high incidence of
aGVHD, while a higher CD56dim/CD56bri NK cell ratio (more
than 8.0) in allografts was correlated with a decreased risk of III-
IV aGVHD.
Relapse Tranplant-related mortality and survival: The 3-year
probability of relapse in the standard-risk group was 11.9%
and 24.3% for AML and ALL and that in high-risk group was
20.2% and 48.5% for AML and ALL, respectively. The advanced
disease status, Higher CD4/CD8 in G-BM and delayed lympho-
cyte recovery at day 30 post transplantation are correlated with
increased relapse rate. While, a higher CD56dim/CD56bri NK
cell ratio (more than 8.0) was correlated with a decreased rate
of relapse. Modified DLI can be used to treat relapse of patients
after the protocol.
The TRM on day 100 in the standard- and high-risk groups was
6.8% and 5.9% for AML and 6.9% and 25.9% for ALL, respectively.
The 3-year probability of LFS for AMLwas 70.7% and 55.9% and
for ALL was 59.7% and 24.8% in the standard-risk and high-risk
groups, respectively.304
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Background: Transforming growth factor-ß(TGFß) and IL10 are
pleiotropic regulatory cytokines in the immune system. Clinical
data and animal model suggest TGFß and IL10 can suppress
aGVHD. The present study was designed to test the influence of
gene polymorphisms of TGFß and IL10 on outcomes after related
and unrelated HSCT.
Methods:We analysed six single nucleotide polymorphisms (SNPs)
in three genes, TGFß1-509(C.T), +869 (T.C), TGFß1 receptor
II (TGFß1RII) +1167 (C.T) and IL10 -1082(A.G),
-819(T.C), -592(A.C), in a cohort of 138 pairs of recipients
and their unrelated donors and a second cohort of 102 pairs of recip-
ients and their HLA-identical sibling donors, who had undergone
HSCT from January 2001 to March 2009 at our center.
Results: (1) TGFß1 -509 T/T genotype in the donors side or T al-
lele-positive in the recipients side showed a significant protective ef-
fect on the occurrence of aGVHD and grade II-IV aGVHD in the
unrelated transplantation cohort (P\0.05). In the combined cohort,
the multivariate analysis confirmed that donors with TGFß1-509 T/
T genotype had a protective effect on the risk of aGVHD. (2) Both in
unrelated transplantation cohort and sibling transplantation cohort,
We found the IL10-819 C/C and -592 C/C genotype in either recip-
ients side or donors side were significantly associated with a higher
incidence of aGVHD (P\0.05). (3) In the combined cohort, the
promoter haplotypes of IL10 polymorphic features in positions
-1082, -819 and -592 had an influence on the occurrence of aGVHD
and death in remission. Recipients without A-T-A haplotype or were
transplanted from donors without A-T-A haplotype had a higher in-
cidence of aGVHD and death in remission than with A-T-A homo-
zygous or heterozygous. In multivariate analysis, recipients without
A-T-A haplotype was found to be associated with a higher risk of
aGVHD (RR5 0.764; P5 0.096) and grade II-IV aGVHD
(RR5 0.413; P5 0.009). (4) No significant association with
aGVHD was detected for the TGFß1 + 869, TGFß1RII +1167and IL10-1082 genotypes. No significant association was found be-
tween cytokine genes polymorphisms with cGVHD, relapse and
overall survival.
Conclusions:This is the first report of the relation of gene polymor-
phisms of IL10, TGFß1 and TGFß1RII to outcomes of allo-HSCT
within Chinese population. The results may provide useful informa-
tion to risk assessment, donor selection, and a guide for appropriate
immunosuppressive therapy.305
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Duran-Struuck, R.1, Teague, A.1, Crepeau, R.1, Matar, A.1,
Henakamp, I.1, Pathiraja, V.1, Veillette, G.1, Spitzer, T.R.2,
Sachs, D.H.1, Bronson, R.T.3, Huang, C.1 1Massachusetts General Hospi-
tal (Harvard Medical School), Boston, MA; 2Massachusetts General Hos-
pital (Harvard Medical School), Boston, MA; 3Harvard Medical School,
Boston, MA
Haploidentical HCT (haplo-HCT) is a potent and potentially cu-
rative therapy for a number of lymphohematopoietic neoplasms.
Haplo-HCT has been limited by toxic conditioning regimens and
the development of lethal graft-versus-host disease (GVHD). Similar
to what has been observed in the clinic, myeloablative HCT out-
comes in the pig have a high incidence of GVHD. Less toxic, non-
myeloablative haplo-HCTs developed in our laboratory resulted in
a greatly reduced incidence and intensity of GvHD. However,
post-transplantation lymphoproliferative disease (PTLD) was often
observed following these novel reduced intensity conditioning proto-
cols. Haplo-HCT conditioning with 700-1000 cGy thymic irradia-
tion (TI), CD3 immunotoxin and 30-60 days of cyclosporine had
a 6% incidence ofGVHD (2 of 32) but was complicated by a 33% in-
cidence of PTLD (11 of 32). Of these 11 pigs, 2 resolved their PTLD
after cyclosporine was discontinued but then developed GVHD.
When thymic irradiation was eliminated from the protocol, no
PTLD was observed and GVHD was only observed in 2 of 24
(8.3%) transplanted pigs. Unfortunately this very mild preparatory
regimen without TI failed to consistently achieve successful long
term engraftment. In an attempt to decrease the incidence of
PTLD, avoid GVHD and increase haplo-HCT engraftment out-
comes, 100 cGy of total body irradiation (TBI) was introduced to
the protocol.Of 46 haplo-HCTrecipients, only 4 (\10%) developed
PTLD and 2/46 animals developed GVHD, one of which recovered
spontaneously. We also attempted to identify serum markers for di-
agnosingPTLDin our pigs. As it is observed in humans,we identified
lactate dehydrogenase (LDH), to be elevated in pigs prior to onset of
PTLD. In support of these findings, three porcine PTLD tumor cell
lines harvested from animals and passaged in vitro demonstrate
higher LDH levels compared to naı¨ve PBMCs. We conclude that:
(1) our current haplo-HCT protocol utilizing 100 cGy TBI, porcine
CD3 immunotoxin and 45 days of cyclosporine is relatively safe and
significantly reduces the incidence of PTLD; (2) stable engraftment
and multilineage chimerism can be achieved with minimal GVHD;
and (3) LDH is a clinically relevant serum marker for the diagnosis
of PTLD in the pig. These findings reinforce the pigmodel as a valu-
able tool for HCT translational studies.306
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Clofarabine (Clo) is a nucleoside analog (NA) with improved an-
tileukemic efficacy compared with Fludarabine (Flu), previously
used with IV Busulfan (Bu) in reduced toxicity conditioning therapy
for Allo-SCT. In vitro studies of [Clo + Flu + Bu] demonstrated a su-
perior synergistic cytotoxicity compared with either [Clo + Bu] or
[Flu + Bu].We have now investigated [Clo6 Flu] with IV Bu in pre-
transplant conditioning.
